These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Binding of soluble recombinant HIV envelope glycoprotein, rgp120, induces conformational changes in the cellular membrane-anchored CD4 molecule. Yachou A; Sékaly RP Biochem Biophys Res Commun; 1999 Nov; 265(2):428-33. PubMed ID: 10558884 [TBL] [Abstract][Full Text] [Related]
8. Improved design of an antigen with enhanced specificity for the broadly HIV-neutralizing antibody b12. Pantophlet R; Wilson IA; Burton DR Protein Eng Des Sel; 2004 Oct; 17(10):749-58. PubMed ID: 15542540 [TBL] [Abstract][Full Text] [Related]
9. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Saphire EO; Parren PW; Pantophlet R; Zwick MB; Morris GM; Rudd PM; Dwek RA; Stanfield RL; Burton DR; Wilson IA Science; 2001 Aug; 293(5532):1155-9. PubMed ID: 11498595 [TBL] [Abstract][Full Text] [Related]
10. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies. Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663 [TBL] [Abstract][Full Text] [Related]
11. Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Koch M; Pancera M; Kwong PD; Kolchinsky P; Grundner C; Wang L; Hendrickson WA; Sodroski J; Wyatt R Virology; 2003 Sep; 313(2):387-400. PubMed ID: 12954207 [TBL] [Abstract][Full Text] [Related]
12. Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope. Darbha R; Phogat S; Labrijn AF; Shu Y; Gu Y; Andrykovitch M; Zhang MY; Pantophlet R; Martin L; Vita C; Burton DR; Dimitrov DS; Ji X Biochemistry; 2004 Feb; 43(6):1410-7. PubMed ID: 14769016 [TBL] [Abstract][Full Text] [Related]
13. Is the V3 loop involved in HIV binding to CD4? Dettin M; Ferranti P; Scarinci C; Picariello G; Di Bello C Biochemistry; 2003 Aug; 42(30):9007-12. PubMed ID: 12885233 [TBL] [Abstract][Full Text] [Related]
14. Antibody neutralization of human immunodeficiency virus type 1 (HIV-1). Schønning K APMIS Suppl; 2003; (111):1-42. PubMed ID: 12739253 [No Abstract] [Full Text] [Related]
16. Towards a structure of the HIV-1 envelope glycoprotein gp120: an immunochemical approach. Moore JP; Jameson BA; Sattentau QJ; Willey R; Sodroski J Philos Trans R Soc Lond B Biol Sci; 1993 Oct; 342(1299):83-8. PubMed ID: 7904352 [TBL] [Abstract][Full Text] [Related]
17. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate. Shibata J; Yoshimura K; Honda A; Koito A; Murakami T; Matsushita S J Virol; 2007 Apr; 81(8):3757-68. PubMed ID: 17251298 [TBL] [Abstract][Full Text] [Related]
18. Selection and characterization of an HIV-1 gp120-binding affibody ligand. Wikman M; Rowcliffe E; Friedman M; Henning P; Lindholm L; Olofsson S; Ståhl S Biotechnol Appl Biochem; 2006 Sep; 45(Pt 2):93-105. PubMed ID: 16712522 [TBL] [Abstract][Full Text] [Related]
19. B cell antigenic site mapping of HIV-1 glycoproteins. Neurath AR Chem Immunol; 1993; 56():34-60. PubMed ID: 8452653 [No Abstract] [Full Text] [Related]